Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

NCT02203526 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

68

Enrollment

NIH

Sponsor class

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: Isavuconazole
DRUG: TEDDI
BIOLOGICAL: Rituximab
DRUG: Cytarabine
DRUG: TEDD
DRUG: Ibrutinib (Arms 2, 3 and 4)
DRUG: Methotrexate
DRUG: Ibrutinib (Arm 1 - Closed with Amendment G)
DRUG: Ibrutinib (Arm 4)

Sponsor

National Cancer Institute (NCI)